CDRI osteoporosis drug to be developed in USA
Central Drug Research Institute (CDRI) provides exclusive licensing to Aveta Biomics, USA of its patented technology of Caviunin-based drug compositions for further clinical development and commercialization.
Worldwide, one in three women and one in five men over the age of 50 years will suffer an osteoporotic fracture. In the US alone, an estimated 10 million people over the age of 50 years have osteoporosis and one in two women in the United States will sustain a fragility fracture in her lifetime.